Safety and effectiveness of dupilumab in the real‐world treatment of atopic dermatitis in Japan: 1‐year interim analysis from a post‐marketing surveillance

Safety and effectiveness of dupilumab in the real‐world treatment of atopic dermatitis in Japan: 1‐year interim analysis from a post‐marketing surveillance

Abstract Objectives Atopic dermatitis (AD) is a common chronic inflammatory skin disorder in Japan. Dupilumab, a fully human monoclonal antibody, targets a shared subunit of the interleukin (IL)‐4 and IL‐13 receptors. Post‐marketing surveillance of the safety and effectiveness of dupilumab in adult...

Full description

Bibliographic Details
Main Authors: Hidehisa Saeki, Hiroyuki Fujita, Katsuhisa Suzuki, Kazuhiko Arima
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Journal of Cutaneous Immunology and Allergy
Subjects:
atopic dermatitis
biologics
dupilumab
Japan
post‐marketing surveillance
Online Access:https://doi.org/10.1002/cia2.12303

Internet

https://doi.org/10.1002/cia2.12303

Similar Items